{"id":659,"date":"2015-07-30T15:25:57","date_gmt":"2015-07-30T09:55:57","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=659"},"modified":"2023-02-10T11:23:37","modified_gmt":"2023-02-10T05:53:37","slug":"pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","title":{"rendered":"PD-1 and PD-L1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2015 &#8211; A DelveInsight Report"},"content":{"rendered":"<p><em><strong>DelveInsight<\/strong><\/em> has made strong presence in Oncology market with&nbsp;<strong>100+<\/strong><strong>&nbsp;<\/strong>Reports on Oncology based&nbsp;<strong>Indications &amp; Mechanism of Action (MOA).<\/strong>DelveInsight Report, <em><strong>PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2015<\/strong><\/em> has received great response and feedback&nbsp;from clients.<\/p>\n\n\n<p>PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1\/PD-L1 inhibitors look to be the most promising in treating cancer.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img decoding=\"async\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300\" alt=\"1067742_deactivated-tcell-pd1-pdl1-14\" class=\"wp-image-517\"\/><\/figure><\/div>\n\n\n<h2 class=\"wp-block-heading\"><em><strong>Key Highlights of the Report:<\/strong><\/em><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Overview of<strong> PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA)<\/strong> and <strong>biomarkers of PD-1 and PD-L1 inhibitors<\/strong> Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented into major geographies<\/li>\n\n\n\n<li>The report has covered the <strong>worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules<\/strong> including along with <strong>patent expiry<\/strong> and impact on market after expiry and detail profiling of Pipeline assets<\/li>\n\n\n\n<li>Key topics covered include<strong> strategic competitor assessment<\/strong>, market characterization, opportunities, barriers and challenges in the market along with <strong>SWOT analysis<\/strong> of the PD-1 and PD-L1 inhibitors market<\/li>\n\n\n\n<li><strong>Pipeline analysis<\/strong>: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates<\/li>\n\n\n\n<li>Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of the market with upcoming blockbuster molecules and their impact on the overall market.<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img decoding=\"async\" width=\"579\" height=\"245\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/pd1.jpg?w=300\" alt=\"pD1\" class=\"wp-image-660\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/pd1.jpg 579w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/pd1-300x127.jpg 300w\" sizes=\"(max-width: 579px) 100vw, 579px\" \/><\/figure><\/div>\n\n\n<p>According to the analysis, <em><strong>34 drugs* are in pipeline<\/strong><\/em>. Out of <em><strong>34, 22* are in combination development with other therapeutics agents future<\/strong><\/em> competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. The market for PD-1 and PD-L1 drugs might be billions of dollars richer than many believe. These drugs which include <em><strong>Bristol-Myers\u2019 Opdivo and Merck\u2019s Keytruda<\/strong><\/em>, are going to be Blockbuster in upcoming years.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img decoding=\"async\" width=\"579\" height=\"307\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/untitled1.jpg?w=300\" alt=\"Untitled\" class=\"wp-image-661\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/untitled1.jpg 579w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/07\/untitled1-300x159.jpg 300w\" sizes=\"(max-width: 579px) 100vw, 579px\" \/><\/figure><\/div>\n\n\n<p>Delveinsight report on PD-1 and PD-L1 help companies in understanding Oncology&nbsp;<strong>market dynamics<\/strong>&nbsp;and therefore giving opportunities for&nbsp;a <strong>strategic alliance&nbsp;that will result in&nbsp;market penetration&nbsp;and&nbsp;enhancement of portfolios with optimal investment and maximal return<\/strong>. In addition, reports will assuage companies to detect&nbsp;<strong>specific tumors<\/strong>, determine&nbsp;<strong>genetic predisposition<\/strong>&nbsp;and&nbsp;<strong>biological response to cancer therapy<\/strong>.<\/p>\n\n\n\n<p>DelveInsight is offering the Report at a price of <em><strong>USD&nbsp;2,950<\/strong><\/em> as a single user license, <em><strong>USD 5,900&nbsp;<\/strong><\/em>as a site license and <em><strong>USD 8,850<\/strong><\/em> as a Global\/Enterprise License.<\/p>\n\n\n\n<p><strong>For more information mail us at <a href=\"mailto:info@delveinsight.com\">info@delveinsight.com<\/a><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>About Us<\/strong><\/h2>\n\n\n\n<p>DelveInsight is a leading Business Consulting and Market Research Firm.&nbsp; We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has made strong presence in Oncology market with&nbsp;100+&nbsp;Reports on Oncology based&nbsp;Indications &amp; Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback&nbsp;from clients. PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[44,49,116,131,204,206,373,454,455,550],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-659","post","type-post","status-publish","format-standard","hentry","category-articles","tag-100-reports-on-oncology","tag-34-drugs-are-in-pipeline","tag-biomarkers-of-pd-1-and-pd-l1-inhibitors","tag-bristol-myers-opdivo-and-mercks-keytruda","tag-delveinsight","tag-delveinsight-oncology-based-reports","tag-market-pipeline-analysis","tag-pd-1-and-pd-l-1-inhibitors","tag-pd-1-and-pd-l-1-inhibitors-competitive-landscape","tag-swot-analysis","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PD-1 and PD-L1 inhibitors Market and Competitive Landscape<\/title>\n<meta name=\"description\" content=\"The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PD-1 and PD-L1 inhibitors Market and Competitive Landscape\" \/>\n<meta property=\"og:description\" content=\"The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-30T09:55:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T05:53:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PD-1 and PD-L1 inhibitors Market and Competitive Landscape","description":"The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","og_locale":"en_US","og_type":"article","og_title":"PD-1 and PD-L1 inhibitors Market and Competitive Landscape","og_description":"The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry","og_url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-30T09:55:57+00:00","article_modified_time":"2023-02-10T05:53:37+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","url":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2","name":"PD-1 and PD-L1 inhibitors Market and Competitive Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300","datePublished":"2015-07-30T09:55:57+00:00","dateModified":"2023-02-10T05:53:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015-2#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/1067742_deactivated-tcell-pd1-pdl1-14.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">100+ Reports on Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">34 drugs* are in pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">biomarkers of PD-1 and PD-L1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bristol-Myers\u2019 Opdivo and Merck\u2019s Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Delveinsight oncology based Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SWOT ANALYSIS<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">100+ Reports on Oncology<\/span>","<span class=\"advgb-post-tax-term\">34 drugs* are in pipeline<\/span>","<span class=\"advgb-post-tax-term\">biomarkers of PD-1 and PD-L1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers\u2019 Opdivo and Merck\u2019s Keytruda<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Delveinsight oncology based Reports<\/span>","<span class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors \u2013 Competitive Landscape<\/span>","<span class=\"advgb-post-tax-term\">SWOT ANALYSIS<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 30, 2015","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Jul 30, 2015 3:25 pm","modified":"Updated on Feb 10, 2023 11:23 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=659"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=659"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=659"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}